Latest News & Features
Europe
Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements. 29 October 2015
Americas
Oppositions to a patent covering the CRISPR/Cas9 system illustrate the need for applicants to carefully consider making statements on commercially important technology even after a patent application has been filed. Catherine Coombes of law firm HGF reports. 29 October 2015
Biotechnology
There is “clearly a lot of unrest” in the patent law on molecular diagnostics, according to the head of licensing at Roche Diagnostics. 28 October 2015
Americas
The Coalition for Affordable Drugs, an organisation closely tied to hedge fund manager Kyle Bass, has persuaded the Patent Trial and Appeal Board to institute an inter partes review concerning the validity of two patents owned by biopharmaceutical company Celgene. 28 October 2015
Americas
Law firm Duane Morris has hired Paul Li as a partner in the firm’s intellectual property practice in San Francisco. 27 October 2015
Americas
Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs have tasted success at the Patent Trial and Appeal Board for the second time in a month after it agreed to institute an inter partes review of a patent covering a drug owned by NPS Pharmaceuticals. 27 October 2015
Asia-Pacific
Pharmaceutical trademark owners in Australia should carefully select and register their marks to minimise potential problems associated with including INNs or INN stems, as Geordie Oldfield of Dennemeyer explains. 27 October 2015
Americas
The future of Brazil’s technological innovation centres, which bring together public and private sector parties to develop mainly life sciences technology, looks bright. Gabriel Di Blasi and Felipe Barros Oquendo of Di Blasi, Parente & Associados report 27 October 2015
Asia
Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further. 27 October 2015
Big Pharma
UK court decisions in Warner-Lambert v Actavis seek to define second medical use patent rights, and the recent full trial ruling provides some early guidance on the ‘reasonable foreseeability’ test concerning patent use, says Steve Smith of Potter Clarkson. 27 October 2015